查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2103779

非專利注射劑市場：全球市場預測，2026-2032年

Generic Injectables Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，非專利注射劑市場規模將成長至 841 億美元，複合年成長率為 11.14%。

主要市場統計數據
基準年 2025 401.4億美元
預計年份：2026年 440.5億美元
預測年份 2032 841億美元
複合年成長率 (%) 11.14%

非專利注射劑是重要的醫療必需藥品，可透過靜脈注射、肌肉注射、皮下注射、鞘內注射和其他腸外途徑給藥，用於支持醫院的急診、腫瘤治療、麻醉、抗感染疾病治療、心血管治療、內分泌治療、急診醫學以及慢性病管理。隨著醫療系統對臨床療效相當但價格更低的品牌注射劑替代品的需求日益成長，同時還要滿足無菌性、生物等效性、藥物警戒、穩定性以及供應連續性方面的嚴格要求，通用注射劑的重要性也日益凸顯。該領域的生產面臨許多複雜挑戰，包括無菌處理、冷凍乾燥、低溫運輸管理、顆粒物控制、容器和密封系統的完整性、萃取物和洗脫液的評估以及符合現行藥品生產品質管理規範 (cGMP)。推動需求成長的因素包括人口老化、外科手術量增加、癌症和慢性病負擔加重、重症監護能力的提升、生物製藥製劑療法的普及以及旨在提高藥品可及性的採購政策。同時，該行業也面臨許多壓力，例如藥品短缺、品質問題召回、監管檢查、活性成分濃度、無菌填充和包裝能力有限以及物流脆弱性等。對於生產者、經銷商、醫療服務提供者和政策制定者而言，策略重點不再只是降低成本，而是要確保已開發國家和新興國家的醫療體係都能獲得充足且品質有保障的關鍵注射藥物。

一項將重塑非專利注射劑市場的變革性變革。

受監管現代化、醫療成本控制、醫院採購整合以及無菌藥品生產日益複雜化等因素的驅動，非專利注射劑市場正經歷結構性轉型。監管機構持續強調品管的成熟度、資料完整性、無菌保證、污染控制策略、亞硝胺和雜質風險管理以及基於風險的檢查框架，這提高了市場參與企業的營運門檻。醫療服務提供者越來越重視可靠的供應、治療互換性和處方效率，尤其對於醫院常用的麻醉劑、麻醉劑、抗凝血劑、抗癌注射、電解質和重症監護處方集等產品而言更是如此。從傳統的小分子注射注射到更複雜的製劑（包括長效注射劑、預填充式注射器、緩釋製劑、脂質體製劑和無菌懸浮液）的轉變，提高了技術要求，並提升了專業研發和生產能力的價值。此外，隨著各國政府和醫療衛生系統推動供應來源多元化、區域生產系統冗餘化、戰略性儲備、改進藥品短缺報告機制以及提高活性成分和關鍵成分的透明度以應對已報告的藥品短缺問題，供應鏈正在經歷重塑。永續性也成為一項新的考量因素，製造商正在評估高能耗的無菌設施、包裝廢棄物、溶劑使用、水資源消耗以及低溫運輸效率。這些變化正在創造一個更規範的產業環境，在這個環境中，品質系統、監管靈活性、生產冗餘以及產品系列優先順序將決定企業的長期競爭力。

人工智慧對非專利注射劑的累積影響

人工智慧 (AI) 對非專利注射劑價值鏈的影響日益顯著，尤其是在製劑開發、生產品質、藥物安全監測、需求預測和法規資訊方面。在研發領域，AI 驅動的建模可以輔助複雜注射製劑的輔料選擇、溶解度評估、程式參數最佳化、穩定性評估和等效性評估。在生產領域，機器視覺、異常檢測、預測性維護、數位孿生和進階製程分析有助於識別無菌環境中的偏差，降低批次失敗風險，並加強污染控制策略。 AI 驅動的品管系統可以改善環境監測、無菌檢測、顆粒物檢測、清潔驗證和儀器性能數據的趨勢分析，前提是其輸出在符合合規性的框架內得到檢驗和控制。在供應鏈管理方面，AI 可以改善醫院需求預測、缺貨風險識別、庫存分配、低溫運輸路線最佳化和異常管理。這對於替代藥物有限的緊急醫療尤其重要。藥物安全監測團隊也利用自然語言處理和自動訊號偵測技術來分析來自結構化和非結構化資料來源的不利事件資料。然而，將人工智慧引入非專利注射劑領域需要應對諸多挑戰，例如驗證、可解釋性、網路安全、資料來源、監管可接受性、偏差管理以及人工監督。只有當人工智慧能夠提升品質保證、測試應對力和供應累積，而不是取代現有的科學和監管決策時，其累積效應才能達到最佳效果。

關於非專利注射劑的關鍵區域見解

亞太地區已成為非專利劑生產和消費的重要中心，這得益於其大規模的製藥製造地、不斷擴展的醫院網路、日益沉重的非傳染性疾病負擔以及各國政府為改善民眾獲得價格合理的必需藥品所做的努力。該地區各國正在推動監管協調、藥品安全監測系統和無菌生產能力的提升，同時也關注品質監管、藥品序列化和供應鏈可追溯性。北美地區憑藉其成熟的醫院採購體系、嚴格的監管檢查標準、在急診護理中廣泛使用非專利注射劑以及持續關注藥品短缺、國內供應韌性和基本藥物安全等政策問題，仍然保持著重要的影響力。拉丁美洲的特點是公共採購項目、醫院對給藥療法的需求不斷成長，以及致力於擴大抗癌藥物、感染疾病物、麻醉劑和急救注射劑的可及性，但報銷限制、對進口的依賴以及監管方面的不一致可能會影響產品的供應。歐洲的特點是嚴格的品質標準、集中化的國家級監管流程、成本控制政策以及醫院處方集中持續使用學名藥。此外，該地區還強調緩解藥品短缺、提高供應鏈透明度以及遵守不斷發展的藥品生產品質管理規範 (GMP) 要求。在中東，對醫療基礎設施、專科藥品和本地製藥能力的投資正在穩步推進，注射用學名藥受益於醫院的擴建、慢性病管理需求的成長以及公共部門採購系統的現代化。在非洲，由於注射抗生素、麻醉劑、孕產婦用藥、急救藥品和疫苗的配送基礎設施對醫療服務仍然至關重要，因此存在著顯著改善藥品可及性的機會。該領域的進展取決於加強監管、確保低溫運輸的可靠性、聯合採購、品質保證的進口以及發展區域生產能力。

影響非專利注射劑需求的關鍵群體洞察

在東南亞國協，擴大醫療覆蓋範圍、推動醫院現代化以及加強監管合作，使得該地區在價格合理的無菌藥品和跨境供應夥伴關係日益重要。需求趨勢主要受感染疾病控制、外科手術、癌症治療、孕產婦健康以及慢性病治療需求成長的驅動，同時，本地生產策略也需兼顧品質保證和檢測要求。海灣合作理事會（GCC）國家正在加強三級醫療、專科醫院建設、國家藥品安全目標，並推動採購系統現代化，以滿足麻醉、腫瘤、重症監護、急診醫學和慢性病管理領域對可靠的非專利注射劑的需求。歐盟為非專利注射劑提供了最完善的監管和採購環境之一，其重點在於藥品安全監測、遵守藥品生產品質管理規範（GMP）、環境風險評估以及協調一致的政策以應對藥品短缺。金磚國家由於其龐大的患者群體、不斷擴大的生產能力、公共衛生優先事項以及完善的監管體系，在非專利注射劑的供需趨勢中扮演著核心角色。儘管七國集團對無菌產品的品質、監管科學、供應鏈韌性和醫院採購效率仍抱有很高的期望，但它們仍然面臨著用於緊急醫療和腫瘤治療的關鍵注射短缺的持續風險。北約成員國則將重點放在衛生安全、緊急準備、災害應變和具有韌性的醫療後勤保障上，因此，它們將確保可靠地獲取用於創傷護理、感染控制、麻醉、重症監護和現場醫療救援的關鍵注射劑作為戰略優先事項。

主要國家非專利注射劑藥物的發展趨勢

美國是非專利注射的核心市場，這得益於其在醫院的廣泛應用、嚴格的法律規範、大規模的無菌藥品採購網路以及持續關注防止無菌注射劑短缺的政策。加拿大重視經濟實惠的醫院藥品、品質有保證的進口藥品以及省級醫療保健系統穩定的供應，並專注於短缺報告和供應連續性。墨西哥的需求主要來自不斷擴大的醫療保健服務、區域製造業整合以及對醫院給藥療法的需求。同時，巴西的公共醫療保健系統和醫院基礎設施持續推動對腫瘤科、感染疾病、麻醉科和急診科等常用注射的需求。在英國，非專利注射劑在國家醫療服務體系（NHS）中廣泛應用，採購規範、臨床指南和供不應求管理機制影響供應商的預期。德國、法國、義大利和西班牙是成熟的歐洲醫療保健系統，成本控制、高品質標準、癌症治療、合理使用抗生素、醫院處方集和藥物安全監測等措施都為非專利注射的廣泛應用提供了支持。俄羅斯優先發展國內藥品產能並確保基本藥物供應，影響了其採購、本地生產和醫院供應策略。中國憑藉其生產規模、基於數量的採購改革、更嚴格的監管以及醫院對注射劑日益成長的需求，在該領域扮演著核心角色。印度是全球主要的學名藥生產國，擁有先進的生產技術、出口導向策略以及龐大的國內醫療保健需求，但其品管系統、資料完整性和監管合規性方面仍面臨嚴格審查。日本保持著嚴格的品質和安全標準，人口老化、以醫院為中心的醫療保健體係以及對可靠供應的偏好共同塑造了其需求。澳洲擁有完善的藥品監管環境和優先考慮成本效益高的治療方案和品質保證的公共報銷系統。韓國正透過推動高品質藥品生產、醫院現代化以及提高出口導向無菌藥品生產能力，加強其在區域非專利藥注射劑生態系統中的作用。

為行業領導者提供的實用建議

產業領導者應將品質系統的成熟度、卓越的無菌生產和持續的供應作為核心策略差異化因素。投資於無菌處理、隔離技術、自動化視覺檢測、環境監測、經驗證的數位化系統、污染控制策略和員工培訓，可以降低合規風險並支援可靠的生產。產品組合策略應著重於具有持續臨床需求、監管管道成熟且技術複雜度可控的醫療必需產品，同時也要考慮複雜注射劑，因為差異化能力能帶來強大的競爭優勢。應透過以下方式增強供應韌性：活性成分和關鍵組件的雙重採購、填充和包裝能力的多元化、低溫運輸驗證、基本藥物的庫存緩衝、經驗證的物流合作夥伴，以及與衛生當局和醫院採購負責人就供不應求進行透明溝通。監管回應團隊必須與監管機構保持積極合作，建立健全的資料完整性計劃，進行全面的生命週期管理，並在全球各地做好接受檢查的準備。銷售團隊必須透過展現服務可靠性、對藥物安全監測的快速反應、穩定的產品供應以及超越單價的整體價值，與醫院的採購優先事項保持一致。經營團隊還應有選擇地利用人工智慧和先進的分析技術，重點關注品質監控、需求預測、偏差管理、申訴處理和監管資訊分析等領域的成熟應用。與本地製造商、公共採購機構、物流供應商、醫院網路和醫療機構夥伴關係，可以改善物資取得途徑，同時降低供應中斷帶來的風險。

非專利注射劑分析的調查方法

針對非專利注射劑，一套穩健的調查方法應結合一手資料和二手資料研究、監管審查、產品層面分析以及供應鏈分析。一手資料研究通常包括對無菌生產專家、監管專家、醫院藥劑師、採購負責人、批發商、臨床醫生、物流供應商和品質保證經理的訪談。二手資料研究應利用已驗證的資訊來源，例如藥品監管機構、藥典標準、藥品短缺資料庫、檢查觀察、公共採購文件、臨床指南、同行檢驗期刊、適用的海關和貿易出版刊物以及公共衛生出版物。分析應評估資訊來源領域、劑型、給藥途徑、生產技術、包裝、監管管道、短缺頻率、品質風險指標、藥物安全監測訊號以及區域可近性趨勢。資料檢驗應包括跨獨立資訊來源的檢驗、一致性檢查、專家審查以及剔除未經證實的說法。非專利注射劑產業受到嚴格監管，且對品質缺陷極為敏感；因此，調查方法應特別注重證據的可追溯性、當前的監管環境、生產合規性訊號以及實際醫療使用模式。這種方法應該避免推測性的假設，而是專注於檢驗的趨勢、已記錄的政策發展和可觀察的營運趨勢。

結論：為非專利注射藥物建構一個穩健的未來。

非專利注射劑在現代醫療保健中佔據著至關重要的地位，它使患者能夠以可負擔的價格獲得醫院、急診醫學、外科手術、腫瘤科、感染疾病治療、麻醉和慢性病管理等領域使用的基本無菌藥物。隨著監管機構、醫療服務提供者和採購系統越來越重視品質、可靠性、無菌性和透明度，該行業面臨日益成長的技術需求。儘管區域趨勢有所不同，但通用的優先事項是可及性、合規性、韌性和可負擔性。人工智慧、自動化和先進的分析技術，在檢驗的品質和法律規範內應用，可以提升這一領域，尤其是在無菌生產控制、偏差檢測、藥物安全監測和供應鏈風險管理方面。擁有強大的合規文化、多元化的供應網路、嚴謹的產品系列、健全的數據管治和快速的客戶響應能力的相關人員，將更有能力支持醫療保健系統應對日益成長的安全可靠的學名藥需求。學名藥的未來不僅取決於價格，更取決於能否在任何需要的地方持續供應高品質、臨床必需的藥物。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：非專利注射劑市場：依藥物類別分類

  • 感染疾病物
    • 抗生素
    • 抗病毒藥物
    • 抗真菌藥物
    • 抗寄生蟲藥物
  • 心血管藥物
    • 抗高血壓藥物
    • 抗心律不整藥物
    • 抗血栓藥物
  • 中樞神經系統藥物
    • 抗癲癇藥物
    • 抗精神病藥物
    • 抗焦慮藥物
  • 荷爾蒙製劑
    • 胰島素
    • 性腺激素
  • 抗癌藥物
    • 細胞毒性藥物
    • 標靶治療
    • 支持療法抗癌藥物
  • 止痛藥和麻醉劑
    • 鴉片類鎮痛藥
    • 非鴉片類鎮痛藥
    • 全身麻醉劑
    • 局部麻醉劑
  • 血液科藥物
    • 止血劑
    • 造血因子
  • 免疫調節劑
    • 免疫抑制劑
    • 免疫促效劑
  • 胃腸道藥物
    • 抗潰瘍藥物
    • 止吐藥
    • 運動興奮劑

第8章：非專利注射劑市場：依給藥途徑分類

  • 靜脈
  • 肌肉內部
  • 皮下
  • 皮內給藥
  • 鞘內腔
  • 關節內
  • 腹腔內

第9章：非專利注射劑市場：依容器類型分類

  • 管瓶
    • 單劑量管瓶
    • 多管瓶小瓶
  • 安瓿
  • 預填充式注射器
  • 墨水匣
  • 筆式和自動注射器

第10章：非專利學名藥市場：依治療領域分類

  • 腫瘤學
    • 固體癌
    • 骨髓惡性腫瘤
    • 支持性護理
  • 感染疾病物
    • 抗生素
    • 抗病毒藥物
    • 抗真菌藥物
    • 抗寄生蟲藥物
  • 心血管系統
    • 高血壓
    • 心臟衰竭
    • 心律不整
    • 抗血栓治療
  • 中樞神經系統
    • 麻醉
    • 疼痛管理
    • 癲癇
    • 精神疾病
  • 內分泌/代謝
    • 糖尿病
    • 甲狀腺疾病
  • 消化器官系統
    • 與酸相關的疾病
    • 發炎性腸道疾病
  • 呼吸系統
    • 氣喘
    • 慢性阻塞性肺病
  • 免疫學
    • 自體免疫疾病
    • 預防移植排斥反應
  • 血液學（非腫瘤）
    • 貧血
    • 凝血障礙

第11章：非專利注射藥品市場：依通路分類

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第12章：非專利注射劑市場：依最終用戶分類

  • 醫院
    • 公立醫院
    • 私立醫院
  • 門診手術中心
  • 診所
  • 家庭醫療保健
  • 診斷和影像中心

第13章：非專利注射劑市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：非專利注射市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：非專利注射劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Amgen Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Baxter International Inc.
  • Biocon Limited
  • Biological E. Limited
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius Kabi AG
  • Gland Pharma Limited by Shanghai Fosun Pharmaceutical Co., Ltd.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Mallinckrodt Pharmaceuticals plc
  • Meitheal Pharmaceuticals, Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Samsung Biologics Co., Ltd.
  • Sanofi SA
  • Somerset Pharma, LLC
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-C002B1C997E0

The Generic Injectables Market is projected to grow by USD 84.10 billion at a CAGR of 11.14% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 40.14 billion
Estimated Year [2026] USD 44.05 billion
Forecast Year [2032] USD 84.10 billion
CAGR (%) 11.14%

Generic injectables are essential medicines delivered through intravenous, intramuscular, subcutaneous, intrathecal, and other parenteral routes, supporting acute care, oncology, anesthesia, anti-infective therapy, cardiovascular treatment, endocrinology, emergency medicine, and hospital-based chronic disease management. Their importance is rising as health systems seek clinically equivalent, lower-cost alternatives to branded injectable drugs while maintaining stringent requirements for sterility, bioequivalence, pharmacovigilance, stability, and supply continuity. The segment is shaped by complex manufacturing barriers, including aseptic processing, lyophilization, cold-chain handling, particulate control, container-closure integrity, extractables and leachables assessment, and compliance with current good manufacturing practices. Demand is influenced by aging populations, increasing surgical volumes, growing cancer and chronic disease burden, expanding intensive care capacity, broader access to biologic-adjacent therapies, and procurement policies designed to improve medicine affordability. At the same time, the sector faces persistent pressure from drug shortages, quality-related recalls, regulatory inspections, active pharmaceutical ingredient concentration, limited sterile fill-finish capacity, and logistics vulnerabilities. For manufacturers, distributors, healthcare providers, and policymakers, the strategic priority is no longer simply cost reduction; it is resilient, quality-assured access to critical injectable medicines across developed and emerging healthcare systems.

Transformative Shifts Reshaping Generic Injectables

The generic injectables landscape is undergoing structural transformation driven by regulatory modernization, healthcare cost containment, hospital procurement consolidation, and rising complexity in sterile drug manufacturing. Regulators continue to emphasize quality management maturity, data integrity, sterility assurance, contamination control strategies, nitrosamine and impurity risk management, and risk-based inspection frameworks, raising the operational threshold for market participation. Healthcare providers are increasingly prioritizing reliable supply, therapeutic interchangeability, and formulary efficiency, particularly for high-use hospital products such as antibiotics, anesthetics, anticoagulants, oncology injectables, electrolytes, and critical care medicines. The shift from conventional small-molecule injectables toward more complex formulations, including long-acting injectables, prefilled syringes, depot formulations, liposomal products, and sterile suspensions, is expanding technical requirements and increasing the value of specialized development and manufacturing capabilities. Supply chains are also being redesigned as governments and health systems respond to documented medicine shortages by encouraging multi-source supply, regional manufacturing redundancy, strategic stockpiles, improved shortage reporting, and better visibility into active ingredients and critical components. Sustainability is emerging as an additional consideration, with manufacturers evaluating energy-intensive sterile facilities, packaging waste, solvent use, water consumption, and cold-chain efficiency. These shifts are creating a more disciplined industry environment in which quality systems, regulatory agility, manufacturing redundancy, and portfolio prioritization determine long-term competitiveness.

Cumulative Impact of Artificial Intelligence on Generic Injectables

Artificial intelligence is increasingly influencing the generic injectables value chain, especially in formulation development, manufacturing quality, pharmacovigilance, demand planning, and regulatory intelligence. In research and development, AI-enabled modeling can support excipient selection, solubility assessment, process parameter optimization, stability evaluation, and comparability assessment for complex injectable formulations. In manufacturing, machine vision, anomaly detection, predictive maintenance, digital twins, and advanced process analytics help identify deviations in aseptic environments, reduce batch failure risk, and strengthen contamination control strategies. AI-supported quality systems can improve trend analysis across environmental monitoring, sterility testing, particulate detection, cleaning validation, and equipment performance data, provided outputs are validated and governed within compliant frameworks. In supply chain management, AI can improve hospital demand sensing, shortage risk identification, inventory allocation, cold-chain route optimization, and exception management, which is particularly relevant for critical care injectables with limited substitution options. Pharmacovigilance teams are also using natural language processing and automated signal detection to analyze adverse event data from structured and unstructured sources. However, AI adoption in generic injectables must address validation, explainability, cybersecurity, data provenance, regulatory acceptability, bias control, and human oversight. The cumulative impact is strongest where AI enhances quality assurance, inspection readiness, and supply resilience rather than replacing established scientific and regulatory decision-making.

Key Regional Insights Across Generic Injectables

Asia-Pacific is a major hub for generic injectable production and consumption, supported by large pharmaceutical manufacturing bases, expanding hospital networks, rising noncommunicable disease burden, and government efforts to improve access to affordable essential medicines. Countries across the region are strengthening regulatory alignment, pharmacovigilance systems, and sterile manufacturing capacity while addressing quality oversight, serialization, and supply chain traceability. North America remains highly influential because of mature hospital purchasing systems, strict regulatory inspection standards, widespread use of injectable generics in acute care, and sustained policy attention on drug shortages, domestic supply resilience, and essential medicine security. Latin America is shaped by public procurement programs, growing demand for hospital-administered therapies, and efforts to expand access to oncology, anti-infective, anesthetic, and emergency care injectables, although reimbursement constraints, import dependence, and regulatory heterogeneity can affect product availability. Europe is characterized by rigorous quality expectations, centralized and national regulatory pathways, cost-containment policies, and sustained use of generic injectables in hospital formularies; the region also emphasizes medicine shortage mitigation, supply chain transparency, and compliance with evolving good manufacturing practice requirements. The Middle East is investing in healthcare infrastructure, specialty care, and local pharmaceutical capability, with generic injectables benefiting from hospital expansion, chronic disease management needs, and public-sector procurement modernization. Africa presents a significant access-driven opportunity, as injectable antibiotics, anesthetics, maternal health medicines, emergency care products, and vaccine-related delivery infrastructure remain critical to healthcare delivery; progress depends on regulatory strengthening, cold-chain reliability, pooled procurement, quality-assured imports, and regional manufacturing development.

Key Group Insights Influencing Generic Injectable Demand

ASEAN countries are advancing healthcare coverage, hospital modernization, and regulatory cooperation, making the region increasingly relevant for affordable sterile medicines and cross-border supply partnerships. Demand patterns are influenced by infectious disease management, surgical care, oncology access, maternal health, and growing chronic disease treatment needs, while local production strategies are being balanced against quality assurance and inspection requirements. The GCC is strengthening tertiary care, specialty hospitals, national pharmaceutical security objectives, and procurement modernization, supporting demand for reliable generic injectables in anesthesia, oncology, intensive care, emergency medicine, and chronic disease management. The European Union provides one of the most structured regulatory and procurement environments for injectable generics, with emphasis on pharmacovigilance, good manufacturing practice compliance, environmental risk considerations, and coordinated policies addressing medicine shortages. BRICS economies combine large patient populations, expanding manufacturing capacity, public health priorities, and increasing regulatory sophistication, making them central to both supply and demand dynamics in generic injectables. G7 countries continue to set high expectations for sterile product quality, regulatory science, supply chain resilience, and hospital procurement efficiency, while also facing persistent shortage risks for essential injectable medicines used in critical care and oncology. NATO countries, because of their focus on health security, emergency preparedness, disaster response, and resilient medical logistics, place strategic importance on dependable access to critical injectables used in trauma care, infection control, anesthesia, intensive care, and field medical readiness.

Key Country Insights for Generic Injectables

The United States is a core generic injectables market due to extensive hospital utilization, advanced regulatory oversight, large sterile drug procurement networks, and persistent policy focus on preventing shortages of sterile injectable drugs. Canada emphasizes cost-effective hospital medicines, quality-assured imports, and stable access across provincial healthcare systems, with attention to shortage reporting and supply continuity. Mexico benefits from expanding healthcare access, regional manufacturing integration, and demand for hospital-administered therapies, while Brazil's public health system and hospital infrastructure create sustained need for essential injectable therapies used in oncology, infectious disease, anesthesia, and emergency care. The United Kingdom relies on generic injectables across national health services, with procurement discipline, clinical guidelines, and shortage management shaping supplier expectations. Germany, France, Italy, and Spain are mature European healthcare systems where cost containment, high quality standards, oncology care, antimicrobial stewardship, hospital formularies, and pharmacovigilance support broad use of injectable generics. Russia has prioritized domestic pharmaceutical capacity and essential medicine availability, influencing procurement, localization, and hospital supply strategies. China is central to the sector through its manufacturing scale, volume-based procurement reforms, regulatory strengthening, and rising hospital demand for injectable therapies. India is a key global producer of generic medicines and sterile injectables, supported by manufacturing expertise, export orientation, and large domestic healthcare needs, while continuing to face intense scrutiny on quality systems, data integrity, and regulatory compliance. Japan maintains stringent quality and safety expectations, with demand shaped by an aging population, hospital-based care, and preference for dependable supply. Australia combines a regulated medicines environment with public reimbursement mechanisms that favor cost-effective treatment options and quality-assured supply. South Korea is advancing high-quality pharmaceutical manufacturing, hospital modernization, and export-oriented sterile drug capabilities, reinforcing its role in the regional generic injectables ecosystem.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize quality system maturity, sterile manufacturing excellence, and supply continuity as core strategic differentiators. Investments in aseptic processing, containment technologies, automated visual inspection, environmental monitoring, validated digital systems, contamination control strategies, and workforce training can reduce compliance risk and support reliable production. Portfolio strategy should focus on medically necessary products with recurring clinical demand, clear regulatory pathways, and manageable technical complexity, while also considering complex injectables where differentiated capabilities create defensible advantages. Supply resilience should be strengthened through dual sourcing of active ingredients and critical components, diversified fill-finish capacity, cold-chain validation, inventory buffers for essential medicines, validated logistics partners, and transparent shortage communication with health authorities and hospital buyers. Regulatory teams should maintain proactive engagement with agencies, robust data integrity programs, lifecycle management discipline, and inspection readiness across global jurisdictions. Commercial teams should align with hospital procurement priorities by demonstrating service reliability, pharmacovigilance responsiveness, product availability, and total value beyond unit price. Leaders should also use AI and advanced analytics selectively, focusing on validated applications in quality monitoring, demand planning, deviation management, complaint handling, and regulatory intelligence. Partnerships with regional manufacturers, public procurement bodies, logistics providers, hospital networks, and healthcare institutions can improve access while reducing vulnerability to supply disruptions.

Research Methodology for Generic Injectables Analysis

A robust research methodology for generic injectables should combine primary and secondary research, regulatory review, product-level mapping, and supply chain analysis. Primary research typically includes interviews with sterile manufacturing experts, regulatory professionals, hospital pharmacists, procurement specialists, distributors, clinicians, logistics providers, and quality assurance leaders. Secondary research should draw from verified sources such as medicine regulatory agencies, pharmacopoeial standards, drug shortage databases, inspection observations, public procurement documents, clinical guidelines, peer-reviewed journals, customs and trade documentation where applicable, and public health organization publications. The analysis should assess therapeutic categories, dosage forms, route of administration, manufacturing technologies, container formats, regulatory pathways, shortage frequency, quality risk indicators, pharmacovigilance signals, and regional access dynamics. Data validation should involve triangulation across independent sources, consistency checks, expert review, and exclusion of unsupported claims. Because the generic injectables sector is highly regulated and sensitive to quality failures, methodology should place special emphasis on evidence traceability, current regulatory status, manufacturing compliance signals, and real-world healthcare utilization patterns. The approach should avoid speculative assumptions and instead focus on verified trends, documented policy developments, and observable operational dynamics.

Conclusion: Building a Resilient Future for Generic Injectables

Generic injectables occupy a critical position in modern healthcare by enabling affordable access to essential sterile medicines used across hospitals, emergency care, surgery, oncology, infectious disease treatment, anesthesia, and chronic disease management. The industry is becoming more technically demanding as regulators, healthcare providers, and procurement systems place greater emphasis on quality, reliability, sterility assurance, and transparency. Regional dynamics differ, but the common priorities are access, compliance, resilience, and affordability. Artificial intelligence, automation, and advanced analytics can strengthen the sector when applied within validated quality and regulatory frameworks, particularly for sterile manufacturing control, deviation detection, pharmacovigilance, and supply chain risk management. Industry participants that combine strong compliance cultures, diversified supply networks, disciplined portfolios, robust data governance, and responsive customer engagement will be better positioned to support healthcare systems facing rising demand for safe and dependable injectable generics. The future of generic injectables will be defined not by price alone, but by the ability to deliver consistent, high-quality, and clinically essential medicines wherever they are needed.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Generic Injectables Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Anti Infectives
    • 7.2.1. Antibacterials
    • 7.2.2. Antivirals
    • 7.2.3. Antifungals
    • 7.2.4. Antiparasitics
  • 7.3. Cardiovascular Agents
    • 7.3.1. Antihypertensives
    • 7.3.2. Antiarrhythmics
    • 7.3.3. Antithrombotic Agents
  • 7.4. Central Nervous System Agents
    • 7.4.1. Antiepileptics
    • 7.4.2. Antipsychotics
    • 7.4.3. Anxiolytics
  • 7.5. Hormonal Agents
    • 7.5.1. Insulins
    • 7.5.2. Gonadal Hormones
  • 7.6. Oncology Agents
    • 7.6.1. Cytotoxic Agents
    • 7.6.2. Targeted Therapies
    • 7.6.3. Supportive Care Oncology Agents
  • 7.7. Analgesics And Anesthetics
    • 7.7.1. Opioid Analgesics
    • 7.7.2. Non Opioid Analgesics
    • 7.7.3. General Anesthetics
    • 7.7.4. Local Anesthetics
  • 7.8. Hematology Agents
    • 7.8.1. Hemostatics
    • 7.8.2. Hematinics
  • 7.9. Immunomodulators
    • 7.9.1. Immunosuppressants
    • 7.9.2. Immunostimulants
  • 7.10. Gastrointestinal Agents
    • 7.10.1. Anti Ulcerants
    • 7.10.2. Antiemetics
    • 7.10.3. Prokinetics

8. Generic Injectables Market, by Route Of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Intramuscular
  • 8.4. Subcutaneous
  • 8.5. Intradermal
  • 8.6. Intrathecal
  • 8.7. Intra Articular
  • 8.8. Intra Peritoneal

9. Generic Injectables Market, by Container Type

  • 9.1. Introduction
  • 9.2. Vials
    • 9.2.1. Single Dose Vials
    • 9.2.2. Multi Dose Vials
  • 9.3. Ampoules
  • 9.4. Prefilled Syringes
  • 9.5. Cartridges
  • 9.6. Pens & Auto Injectors

10. Generic Injectables Market, by Therapeutic Area

  • 10.1. Introduction
  • 10.2. Oncology
    • 10.2.1. Solid Tumors
    • 10.2.2. Hematologic Malignancies
    • 10.2.3. Supportive Care
  • 10.3. Anti Infective
    • 10.3.1. Antibacterial
    • 10.3.2. Antiviral
    • 10.3.3. Antifungal
    • 10.3.4. Antiparasitic
  • 10.4. Cardiovascular
    • 10.4.1. Hypertension
    • 10.4.2. Heart Failure
    • 10.4.3. Arrhythmia
    • 10.4.4. Antithrombotic Therapy
  • 10.5. Central Nervous System
    • 10.5.1. Anesthesia
    • 10.5.2. Pain Management
    • 10.5.3. Epilepsy
    • 10.5.4. Psychiatric Disorders
  • 10.6. Endocrinology And Metabolic
    • 10.6.1. Diabetes
    • 10.6.2. Thyroid Disorders
  • 10.7. Gastrointestinal
    • 10.7.1. Acid Related Disorders
    • 10.7.2. Inflammatory Bowel Disease
  • 10.8. Respiratory
    • 10.8.1. Asthma
    • 10.8.2. Chronic Obstructive Pulmonary Disease
  • 10.9. Immunology
    • 10.9.1. Autoimmune Disorders
    • 10.9.2. Transplant Rejection Prophylaxis
  • 10.10. Hematology Non Oncology
    • 10.10.1. Anemia
    • 10.10.2. Coagulation Disorders

11. Generic Injectables Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Hospital Pharmacies
  • 11.3. Retail Pharmacies
  • 11.4. Online Pharmacies

12. Generic Injectables Market, by End User

  • 12.1. Introduction
  • 12.2. Hospitals
    • 12.2.1. Public Hospitals
    • 12.2.2. Private Hospitals
  • 12.3. Ambulatory Surgical Centers
  • 12.4. Clinics
  • 12.5. Home Healthcare
  • 12.6. Diagnostic And Imaging Centers

13. Generic Injectables Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Generic Injectables Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Generic Injectables Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Amgen Inc.
  • 17.2. AstraZeneca PLC
  • 17.3. Aurobindo Pharma Limited
  • 17.4. Baxter International Inc.
  • 17.5. Biocon Limited
  • 17.6. Biological E. Limited
  • 17.7. Bristol-Myers Squibb Company
  • 17.8. Cipla Limited
  • 17.9. Dr. Reddy's Laboratories Ltd.
  • 17.10. Fresenius Kabi AG
  • 17.11. Gland Pharma Limited by Shanghai Fosun Pharmaceutical Co., Ltd.
  • 17.12. GlaxoSmithKline PLC
  • 17.13. Hikma Pharmaceuticals PLC
  • 17.14. Johnson & Johnson Services, Inc.
  • 17.15. Lupin Limited
  • 17.16. Mallinckrodt Pharmaceuticals plc
  • 17.17. Meitheal Pharmaceuticals, Inc.
  • 17.18. Merck & Co. Inc.
  • 17.19. Novartis AG
  • 17.20. Novo Nordisk A/S
  • 17.21. Pfizer Inc.
  • 17.22. Samsung Biologics Co., Ltd.
  • 17.23. Sanofi S.A.
  • 17.24. Somerset Pharma, LLC
  • 17.25. Sun Pharmaceutical Industries Ltd.
  • 17.26. Teva Pharmaceutical Industries Ltd.
  • 17.27. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENERIC INJECTABLES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL GENERIC INJECTABLES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL GENERIC INJECTABLES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL GENERIC INJECTABLES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL GENERIC INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CONTAINER TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CONTAINER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL GENERIC INJECTABLES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL GENERIC INJECTABLES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL GENERIC INJECTABLES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL GENERIC INJECTABLES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTI INFECTIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI INFECTIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTI INFECTIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIBACTERIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBACTERIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBACTERIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIVIRALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIVIRALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIVIRALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIFUNGALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIFUNGALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIFUNGALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIPARASITICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIPARASITICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIPARASITICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIOVASCULAR AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CARDIOVASCULAR AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARDIOVASCULAR AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIHYPERTENSIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIHYPERTENSIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIHYPERTENSIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIARRHYTHMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIARRHYTHMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIARRHYTHMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTITHROMBOTIC AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTITHROMBOTIC AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTITHROMBOTIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CENTRAL NERVOUS SYSTEM AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CENTRAL NERVOUS SYSTEM AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CENTRAL NERVOUS SYSTEM AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTIEPILEPTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIEPILEPTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTIEPILEPTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIPSYCHOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTIPSYCHOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIPSYCHOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANXIOLYTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANXIOLYTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANXIOLYTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HORMONAL AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HORMONAL AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HORMONAL AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INSULINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INSULINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INSULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GONADAL HORMONES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GONADAL HORMONES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GONADAL HORMONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ONCOLOGY AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONCOLOGY AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ONCOLOGY AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CYTOTOXIC AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CYTOTOXIC AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CYTOTOXIC AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TARGETED THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TARGETED THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SUPPORTIVE CARE ONCOLOGY AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SUPPORTIVE CARE ONCOLOGY AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SUPPORTIVE CARE ONCOLOGY AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANALGESICS AND ANESTHETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANALGESICS AND ANESTHETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANALGESICS AND ANESTHETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL OPIOID ANALGESICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL OPIOID ANALGESICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL OPIOID ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NON OPIOID ANALGESICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NON OPIOID ANALGESICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NON OPIOID ANALGESICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENERAL ANESTHETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GENERAL ANESTHETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENERAL ANESTHETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL LOCAL ANESTHETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL LOCAL ANESTHETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL LOCAL ANESTHETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HEMATOLOGY AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HEMATOLOGY AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HEMATOLOGY AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HEMOSTATICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HEMOSTATICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HEMOSTATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HEMATINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HEMATINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HEMATINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL IMMUNOMODULATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL IMMUNOSTIMULANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL IMMUNOSTIMULANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL IMMUNOSTIMULANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GASTROINTESTINAL AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANTI ULCERANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTI ULCERANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANTI ULCERANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTIEMETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANTIEMETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTIEMETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PROKINETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PROKINETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PROKINETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL INTRADERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL INTRADERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL INTRADERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL INTRATHECAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL INTRATHECAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL INTRATHECAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL INTRA ARTICULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL INTRA ARTICULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL INTRA ARTICULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL INTRA PERITONEAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL INTRA PERITONEAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL INTRA PERITONEAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CONTAINER TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL VIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL VIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL SINGLE DOSE VIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL SINGLE DOSE VIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL SINGLE DOSE VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL MULTI DOSE VIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL MULTI DOSE VIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL MULTI DOSE VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL AMPOULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL AMPOULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL AMPOULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL PREFILLED SYRINGES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL PREFILLED SYRINGES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL PREFILLED SYRINGES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CARTRIDGES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CARTRIDGES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CARTRIDGES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL PENS & AUTO INJECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL PENS & AUTO INJECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL PENS & AUTO INJECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL SUPPORTIVE CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL SUPPORTIVE CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL SUPPORTIVE CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL ANTI INFECTIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANTI INFECTIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL ANTI INFECTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL ANTIBACTERIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ANTIBACTERIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANTIBACTERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL ANTIVIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL ANTIVIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL ANTIVIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL ANTIFUNGAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL ANTIFUNGAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL ANTIFUNGAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL ANTIPARASITIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL ANTIPARASITIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL ANTIPARASITIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL HYPERTENSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL HYPERTENSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL HEART FAILURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL HEART FAILURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL ARRHYTHMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL ARRHYTHMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL ARRHYTHMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL ANTITHROMBOTIC THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL ANTITHROMBOTIC THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL ANTITHROMBOTIC THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL ANESTHESIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL ANESTHESIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL ANESTHESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL EPILEPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL EPILEPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL EPILEPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL PSYCHIATRIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL PSYCHIATRIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL PSYCHIATRIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL ENDOCRINOLOGY AND METABOLIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL ENDOCRINOLOGY AND METABOLIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL ENDOCRINOLOGY AND METABOLIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL THYROID DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL THYROID DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL THYROID DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL GASTROINTESTINAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL GASTROINTESTINAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL GASTROINTESTINAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL ACID RELATED DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL ACID RELATED DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL ACID RELATED DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL RESPIRATORY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL RESPIRATORY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL RESPIRATORY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL ASTHMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL ASTHMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL ASTHMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. GLOBAL IMMUNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL IMMUNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL IMMUNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. GLOBAL TRANSPLANT REJECTION PROPHYLAXIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL TRANSPLANT REJECTION PROPHYLAXIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL TRANSPLANT REJECTION PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. GLOBAL HEMATOLOGY NON ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL HEMATOLOGY NON ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL HEMATOLOGY NON ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. GLOBAL ANEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 251. GLOBAL ANEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL ANEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. GLOBAL COAGULATION DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 254. GLOBAL COAGULATION DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 255. GLOBAL COAGULATION DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 259. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 261. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 262. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 263. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 264. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 265. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 266. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 268. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 269. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 271. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 272. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 273. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 274. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 275. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 276. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 277. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 278. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 279. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 280. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 281. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 283. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 284. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 285. GLOBAL DIAGNOSTIC AND IMAGING CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 286. GLOBAL DIAGNOSTIC AND IMAGING CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 287. GLOBAL DIAGNOSTIC AND IMAGING CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 288. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY CARDIOVASCULAR AGENTS, 2018-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY CENTRAL NERVOUS SYSTEM AGENTS, 2018-2032 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY HORMONAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY ANALGESICS AND ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY HEMATOLOGY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY GASTROINTESTINAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY CONTAINER TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY VIALS, 2018-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY ANTI INFECTIVE, 2018-2032 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY ENDOCRINOLOGY AND METABOLIC, 2018-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY HEMATOLOGY NON ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 316. NORTH AMERICA GENERIC INJECTABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 317. NORTH AMERICA GENERIC INJECTABLES MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 318. NORTH AMERICA GENERIC INJECTABLES MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 319. NORTH AMERICA GENERIC INJECTABLES MARKET SIZE, BY CARDIOVASCULAR AGENTS, 2018-2032 (USD MILLION)
  • TABLE 320. NORTH AMERICA GENERIC INJECTABLES MARKET SIZE, BY CENTRAL NERVOUS SYSTEM AGENTS, 2018-2032 (USD MILLION)
  • TABLE 321. NORTH AMERICA GENERIC INJECTABLES MARKET SIZE, BY HORMONAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 322. NORTH AMERICA GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 323. NORTH AMERICA GENERIC INJECTABLES MARKET SIZE, BY ANALGESICS AND ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 324. NORTH AMERICA GENERIC INJECTABLES MARKET SIZE, BY HEMATOLOGY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 325. NORTH AMERICA GENERIC INJECTABLES MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 326. NORTH AMERICA GENERIC INJECTABLES MARKET SIZE, BY GASTROINTESTINAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 327. NORTH AMERICA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 328. NORTH AMERICA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. NORTH AMERICA GENERIC INJECTABLES MARKET SIZE, BY VIALS, 2018-2032 (USD MILLION)
  • TABLE 330. NORTH AMERICA GENERIC INJECTABLES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 331. NORTH AMERICA GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 332. NORTH AMERICA GENERIC INJECTABLES MARKET SIZE, BY ANTI INFECTIVE, 2018-2032 (USD MILLION)
  • TABLE 333. NORTH AMERICA GENERIC INJECTABLES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 334. NORTH AMERICA GENERIC INJECTABLES MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 335. NORTH AMERICA GENERIC INJECTABLES MARKET SIZE, BY ENDOCRINOLOGY AND METABOLIC, 2018-2032 (USD MILLION)
  • TABLE 336. NORTH AMERICA GENERIC INJECTABLES MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 337. NORTH AMERICA GENERIC INJECTABLES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 338. NORTH AMERICA GENERIC INJECTABLES MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 339. NORTH AMERICA GENERIC INJECTABLES MARKET SIZE, BY HEMATOLOGY NON ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 340. NORTH AMERICA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 341. NORTH AMERICA GENERIC INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 342. NORTH AMERICA GENERIC INJECTABLES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 343. LATIN AMERICA GENERIC INJECTABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 344. LATIN AMERICA GENERIC INJECTABLES MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 345. LATIN AMERICA GENERIC INJECTABLES MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 346. LATIN AMERICA GENERIC INJECTABLES MARKET SIZE, BY CARDIOVASCULAR AGENTS, 2018-2032 (USD MILLION)
  • TABLE 347. LATIN AMERICA GENERIC INJECTABLES MARKET SIZE, BY CENTRAL NERVOUS SYSTEM AGENTS, 2018-2032 (USD MILLION)
  • TABLE 348. LATIN AMERICA GENERIC INJECTABLES MARKET SIZE, BY HORMONAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 349. LATIN AMERICA GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 350. LATIN AMERICA GENERIC INJECTABLES MARKET SIZE, BY ANALGESICS AND ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 351. LATIN AMERICA GENERIC INJECTABLES MARKET SIZE, BY HEMATOLOGY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 352. LATIN AMERICA GENERIC INJECTABLES MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 353. LATIN AMERICA GENERIC INJECTABLES MARKET SIZE, BY GASTROINTESTINAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 354. LATIN AMERICA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 355. LATIN AMERICA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER TYPE, 2018-2032 (USD MILLION)
  • TABLE 356. LATIN AMERICA GENERIC INJECTABLES MARKET SIZE, BY VIALS, 2018-2032 (USD MILLION)
  • TABLE 357. LATIN AMERICA GENERIC INJECTABLES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 358. LATIN AMERICA GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 359. LATIN AMERICA GENERIC INJECTABLES MARKET SIZE, BY ANTI INFECTIVE, 2018-2032 (USD MILLION)
  • TABLE 360. LATIN AMERICA GENERIC INJECTABLES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 361. LATIN AMERICA GENERIC INJECTABLES MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 362. LATIN AMERICA GENERIC INJECTABLES MARKET SIZE, BY ENDOCRINOLOGY AND METABOLIC, 2018-2032 (USD MILLION)
  • TABLE 363. LATIN AMERICA GENERIC INJECTABLES MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 364. LATIN AMERICA GENERIC INJECTABLES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 365. LATIN AMERICA GENERIC INJECTABLES MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 366. LATIN AMERICA GENERIC INJECTABLES MARKET SIZE, BY HEMATOLOGY NON ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 367. LATIN AMERICA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 368. LATIN AMERICA GENERIC INJECTABLES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 369. LATIN AMERICA GENERIC INJECTABLES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 370. EUROPE GENERIC INJECTABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 371. EUROPE GENERIC INJECTABLES MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 372. EUROPE GENERIC INJECTABLES MARKET SIZE, BY ANTI INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 373. EUROPE GENERIC INJECTABLES MARKET SIZE, BY CARDIOVASCULAR AGENTS, 2018-2032 (USD MILLION)
  • TABLE 374. EUROPE GENERIC INJECTABLES MARKET SIZE, BY CENTRAL NERVOUS SYSTEM AGENTS, 2018-2032 (USD MILLION)
  • TABLE 375. EUROPE GENERIC INJECTABLES MARKET SIZE, BY HORMONAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 376. EUROPE GENERIC INJECTABLES MARKET SIZE, BY